We are live on
!
Find out more
CANY
Caxton Associates (New York) Portfolio holdings
AUM
$3.18B
1-Year Est. Return
54.49%
This Fund
S&P 500
This Quarter
Est. Return
+10.11%
1 Year Est. Return
+54.49%
3 Year Est. Return
+73.91%
5 Year Est. Return
+212.89%
10 Year Est. Return
+632.2%
AUM
$663M
AUM Growth
-$835M
(-56%)
Cap. Flow
-$859M
Cap. Flow
% of AUM
-129.52%
Top 10 Holdings %
Top 10 Hldgs %
36.6%
Holding
684
New
251
Increased
107
Reduced
109
Closed
206
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Freeport-McMoran
FCX
|
+$123M |
| 2 |
Alibaba
BABA
|
+$16.4M |
| 3 |
Advanced Micro Devices
AMD
|
+$12.3M |
| 4 |
Mercado Libre
MELI
|
+$12.3M |
| 5 |
Cadence Design Systems
CDNS
|
+$10.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$541M |
| 2 |
iShares Biotechnology ETF
IBB
|
+$152M |
| 3 |
Pfizer
PFE
|
+$147M |
| 4 |
Eli Lilly
LLY
|
+$77.2M |
| 5 |
Gilead Sciences
GILD
|
+$66M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 20.16% |
| 2 | Technology | 17.81% |
| 3 | Consumer Discretionary | 13.64% |
| 4 | Healthcare | 9.49% |
| 5 | Financials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
601
Pfizer
PFE
$154B
| – | – |
-2,874,544
| Closed | -$147M |
|
602
Performance Food Group
PFGC
$17.9B
| – | – |
-11,312
| Closed | -$661K |
|
603
Pentair
PNR
$10.7B
| – | – |
-26,766
| Closed | -$1.2M |
|
|
PR
604
Permian Resources
PR
$17.8B
| – | – |
-15,793
| Closed | -$148K |
|
605
Prelude Therapeutics
PRLD
$385M
| – | – |
-65,453
| Closed | -$395K |
|
606
Personalis
PSNL
$1.55B
| – | – |
-24,524
| Closed | -$48.6K |
|
607
Phillips 66
PSX
$86B
| – | – |
-8,670
| Closed | -$902K |
|
608
Patterson-UTI
PTEN
$4.19B
| – | – |
-32,040
| Closed | -$540K |
|
609
Protagonist Therapeutics
PTGX
$9.71B
| – | – |
-21,853
| Closed | -$238K |
|
610
Qiagen
QGEN
$9.04B
| – | – |
-17,178
| Closed | -$908K |
|
611
CALL
Invesco QQQ Trust
QQQ
$479B
| – | – |
-27,500
| Closed | -$7.32M |
|
|
612
Invesco QQQ Trust
QQQ
$479B
| – | – |
-56,775
| Closed | -$15.1M |
|
|
613
PUT
Invesco QQQ Trust
QQQ
$479B
| – | – |
-62,500
| Closed | -$16.6M |
|
614
Ferrari
RACE
$71.5B
| – | – |
-21,211
| Closed | -$4.58M |
|
615
Transocean
RIG
$6.33B
| – | – |
-218,457
| Closed | -$996K |
|
616
RenaissanceRe
RNR
$13.2B
| – | – |
-2,934
| Closed | -$541K |
|
617
Royalty Pharma
RPRX
$25.8B
| – | – |
-42,786
| Closed | -$1.69M |
|
|
SFIX
618
Stitch Fix
SFIX
$530M
| – | – |
-41,639
| Closed | -$129K |
|
619
VanEck Semiconductor ETF
SMH
$70.1B
| – | – |
-5,000
| Closed | -$507K |
|
620
Semtech
SMTC
$12.2B
| – | – |
-9,183
| Closed | -$263K |
|
621
Scholar Rock
SRRK
$6.32B
| – | – |
-30,620
| Closed | -$277K |
|
622
Simpson Manufacturing
SSD
$8.03B
| – | – |
-3,113
| Closed | -$276K |
|
623
Shutterstock
SSTK
$217M
| – | – |
-9,510
| Closed | -$501K |
|
624
Scorpio Tankers
STNG
$3.83B
| – | – |
-34,981
| Closed | -$1.88M |
|
625
Starwood Property Trust
STWD
$6.16B
| – | – |
-46,166
| Closed | -$846K |
|
Similar funds
BFM
MWM
CCM
ECG
LSAG
KL
WP
RDIA
Caxton Associates (New York)'s Q1 2023 Portfolio in Review
As of Q1 2023, Caxton Associates (New York) held 684 positions worth $663M, down 56% from $1.5B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Caxton Associates (New York) withdrew a net $859M in Q1 2023, closing 206 positions and reducing 109 holdings. Its most notable exit was iShares Biotechnology ETF, an estimated $152M position sold in full.
By sector, the portfolio is most concentrated in Materials at 20% of assets, up from 0.33% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Caxton Associates (New York) opened a new position in Advanced Micro Devices worth $14.8M.
- Caxton Associates (New York)'s largest Q1 2023 buy was Advanced Micro Devices: 151,421 shares worth $14.8M.
- Caxton Associates (New York) added most to Freeport-McMoran in Q1 2023, an estimated $123M increase.
- Caxton Associates (New York)'s biggest Q1 2023 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $541M.
- Caxton Associates (New York) fully exited iShares Biotechnology ETF in Q1 2023, selling an estimated $152M.
- Caxton Associates (New York)'s ten largest holdings make up 37% of its $663M portfolio in Q1 2023.
- Caxton Associates (New York) opened 251 new positions and closed 206 in Q1 2023.
- Caxton Associates (New York)'s portfolio value fell 56% quarter-over-quarter to $663M.
Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.